

## Terms of Reference (ToRs) for the Research IP Strategy Evaluation Committee (RIPSEC)

<p><b>Delegated Authority and Purpose</b></p>	<p>To make recommendations to the Research Performance &amp; Management Committee (RPMC) to commercialise selected BU IP that will generate societal benefit and economic impact and ensure that investment is available to exploit BU’s research IP (including support staff and budget), is appropriately prioritised.</p> <p>Links to BU2025:</p> <p>PRIMARY:</p> <p><i>Action 33: Develop our approach to creating, protecting and exploiting intellectual property</i></p> <p>ASSOCIATED:</p> <p><i>Action 24: Take an innovative and experimental approach to develop our strategic investment areas and engage with external opportunities and partners</i></p> <p><i>Action 26: Define and set priorities for investment: scope the opportunity, our existing strengths, and links to external priorities; develop detailed and flexible investment models; and identify external funding opportunities</i></p> <p><i>Action 30: All academic staff will develop a substantial research profile with impact aligned to our BU2025 outcomes. Academic staff develop their research and its impact and collaborate with and support colleagues to achieve this</i></p>
<p><b>Main responsibilities</b></p>	<ol style="list-style-type: none"> <li>1. Make recommendations to RPMC to commercialise selected BU IP that will generate societal benefit and economic impact.</li> <li>2. To provide clear opinion and judgement to select IP opportunities, which can be de-risked or matured to create equitable acquisition, licensing, academic start-up or spin-out propositions that will most likely secure a revenue stream over and above the commercialisation outlay.</li> <li>3. To provide proportionate, consistent and high-quality review of cost versus potential return on investment to BU of the patent strategy around the selected business opportunity.</li> <li>4. To ensure BU meets its charitable objectives through any commercial exploitation activity and delivers societal impact.</li> <li>5. To ensure that appropriate activities are in place including marketing or business plans in order to secure licensing of IP or creation of a spin-out company on or before the Patent Cooperation Treaty phase initiates.</li> </ol>

	<ol style="list-style-type: none"> <li>6. Make recommendations to RPMC when IP needs to be assigned to a BU IP holding company for onward exploitation.</li> <li>7. Make recommendations as to how BU can build a portfolio of high-quality patents that can be commercialised.</li> <li>8. Review performance of BU's IP exploitation (as defined through the HE-BCI survey/KEF metrics/REF impact case studies) and make recommendations to the KE working Group and the HEIF funding panel chairs as to how it can be enhanced.</li> <li>9. Review historical internal investment made to exploit IP and endorse continued or cessation of funding.</li> <li>10. To examine equality analysis of the recommendations made by RIPSEC and create corresponding remedial actions to ensure IP exploitation at BU is equitable.</li> </ol>
<b>Duration</b>	Permanent
<b>Chair</b>	Executive Dean (to be rotated each year)
<b>Deputy Chair</b>	Deputy Dean for Research & Professional Practice (to be rotated each year)
<b>Management and Support</b>	Research Commercialisation Manager (Secretary) and KE Adviser (Clerk)
<b>Membership</b>	<ul style="list-style-type: none"> <li>- Executive Dean (Chair) to be rotated each year</li> <li>- Deputy Director of Finance or nominated representative</li> <li>- Chair of KE Working Group</li> <li>- Deputy Dean for Research &amp; Professional Practice (x4) or nominated representative</li> <li>- Research Programme Manager</li> <li>- Deputy Head of Legal Services</li> <li>- Chair of HEIF Funding Panel</li> <li>- Clinical Governance Advisor (needed for IP associated with healthcare)</li> <li>- Academic representation (recruited through an open call), including: <ul style="list-style-type: none"> <li>o 1 x IP law specialist</li> <li>o 1 x software development specialist</li> <li>o 1 x PGR</li> <li>o 1 x Early Career Researcher (i.e. within 5 years of being awarded their PhD)</li> </ul> </li> </ul>
<b>Quorum</b>	50% + 1
<b>Usual Number of Meetings</b>	Four meetings per academic year
<b>Reporting Line</b>	RPMC
<b>Minutes</b>	RPMC
<b>Sub-committees</b>	None

<b>Publication</b>	Published on the Staff Intranet
<b>Notes</b>	